Unlikely to what had been observed in murine models, it has been shown that HR-MDS patient samples specifically undergo cell death in response to venetoclax even when harboring mutations in ASXL1, RUNX1, TP53 or EZH2 (228). This evidence concerns the gene TP53 and myelodysplastic syndrome.